Structure Therapeutics Widens Loss as Phase 3 Enrollment Runs

The Tip Desk · November 12, 2026 · 4 min read

The company posted a $144.8 million net loss for the third quarter as research and development spending more than doubled from a year earlier.

Structure Therapeutics Inc. (GPCR), a clinical-stage biopharmaceutical company developing oral small molecule treatments for metabolic disease, reported a net loss of $144.8 million for the third quarter ended September 30, 2026, including $12.7 million of non-cash share-based compensation, compared with a net loss of $65.7 million a year earlier, including $7.5 million of such compensation.

Research and development expenses were $134.6 million, up from $59.0 million in the same period of 2025. The company said the increase was primarily due to clinical trial costs, preclinical research and development expenses, and employee expenses. General and administrative expenses were $21.8 million, versus $14.8 million a year earlier, which the company attributed primarily to employee expenses as it expanded infrastructure to support growth in operations.

Cash, cash equivalents and short-term investments were $1.2 billion as of September 30, 2026, down from $1.3 billion as of June 30, 2026. The company said it expects that cash to fund projected operations and key clinical milestones through 2028, including costs related to the Phase 3 registrational program for aleniglipron, excluding additional pre-commercialization costs including commercial manufacturing.

The Phase 3 ACCOMPLISH program, which began in August 2026, is now enrolling. ACCOMPLISH-1 is enrolling up to 3,600 adults with obesity or overweight and at least one weight-related comorbidity; ACCOMPLISH-2 is enrolling up to 1,100 adults with obesity or overweight and type 2 diabetes. Both trials are randomized, double-blind, placebo-controlled and are designed to support global regulatory submissions for chronic weight management. Participants receive placebo or one of three maintenance doses of aleniglipron (45 mg, 90 mg or 180 mg) after a 2.5 mg starting dose with four-week titration. Topline data are expected in the second half of 2028.

In September 2026 the company reported 72-week results from the ACCESS open-label extension, a prespecified 36-week extension of the Phase 2b ACCESS trial. Participants originally randomized to the 45 mg, 90 mg and 120 mg arms who continued into the extension dosed up to 180 mg. Data showed up to 16.2% mean reduction in body weight in the highest dose group at 72 weeks, with no observed plateau in the two top dose groups, and treatment discontinuation rates of less than 5% due to treatment-emergent adverse events. Two posters on aleniglipron, covering the ACCESS OLE and dose-ranging effects across the ACCESS trials, are scheduled for ObesityWeek 2026 on November 15.

Additional aleniglipron data are expected in the fourth quarter of 2026 from three supplementary trials: a 44-week body composition study, a 30-week study in adults with type 2 diabetes and obesity or overweight, and a SWITCH study evaluating transition from an approved injectable GLP-1 receptor agonist to once-daily oral aleniglipron for weight loss maintenance over 12 weeks.

The company also reported topline results from the single ascending dose portion of its Phase 1/2a trial of ACCG-2671, an oral small molecule dual amylin and calcitonin receptor agonist. Single doses of 1, 2, 5 or 10 mg were given to 31 healthy adults without obesity. ACCG-2671 demonstrated a half-life of approximately 6 days, with no serious adverse events reported. Dosing has begun in the 12-week multiple ascending dose portion, a randomized, placebo-controlled study in participants living with obesity that will evaluate daily and weekly regimens, different titration approaches, and a cohort adding ACCG-2671 to a stable dose of an injectable GLP-1 receptor agonist. Topline MAD data are expected in the first half of 2027.

Chief Executive Officer Raymond Stevens said the company is advancing aleniglipron toward potential registration while building a broader portfolio of oral small molecule treatments for chronic weight management, and that it is developing commercial readiness plans and sees significant opportunity for aleniglipron in both initial weight loss and long-term weight loss maintenance.

The company plans to initiate a Phase 1 trial of second DACRA candidate ACCG-3535 in the fourth quarter of 2026 and expects to initiate a clinical trial of an oral small molecule amylin plus GLP-1 receptor agonist combination in 2027.